While health plans have embraced alternative therapies, there's little agreement on how to bill for them. The ability to demonstrate outcomes may help.
There's a difference between plausibility and wishful thinking that many who predict the advent of this system fail to recognize. Risk adjusting, adverse selection, and the tax code present hurdles.
Despite what might be commonly believed, pharmacoeconomics is not a widely used tool for formulary development. Here's a model to follow.
RED TAPE DEPT.
When it comes to information-sharing, just when does 'no' mean 'no'? What about conflicting statutes? We have two years to sort it out.
Unintentional bias can be just as damaging as the overt brand, according to the president of the National Medical Association.